16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
Public ClinicalTrials.gov record NCT02260193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.
Study identification
- NCT ID
- NCT02260193
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Akebia Therapeutics
- Industry
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- AKB-6548 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 9, 2014
- Primary completion
- Jul 21, 2015
- Completion
- Jul 21, 2015
- Last update posted
- Jun 30, 2022
2014 – 2015
United States locations
- U.S. sites
- 16
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | El Granada | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | San Dimas | California | — | — |
| Not listed | Santa Clarita | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Arvada | Colorado | — | — |
| Not listed | Westminster | Colorado | — | — |
| Not listed | Naples | Florida | — | — |
| Not listed | North Miami Beach | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Astoria | New York | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Grand Prairie | Texas | — | — |
| Not listed | Greenville | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Mechanicsville | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02260193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2022 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02260193 live on ClinicalTrials.gov.